Vivariant Receives Drug Establishment License
Toronto, June 24th, 2022 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce it has received its Drug Establishment License (DEL) number from Health Canada. In…
Vivariant Applies for GMP Certification
Toronto, March 4th, 2022 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce it has received its Drug Establishment License (DEL) application number (52704) from Health…
Vivariant Laboratories, Inc Receives ISO/IEC 17025 Accreditation by CALA
Toronto, February 2, 2022 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce it has achieved the performance benchmark of ISO/IEC 17025 accreditation by Canada Association…
Vivariant Applies for Licensed Dealer (LD) Permit for Psilcybin
Toronto, December 22nd, 2021 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is proud to announce it has submitted an application for a Licensed Dealer (LD) permit to possess…
Vivariant Receives Containment Level II Pathogen and Toxin License
Toronto, January 4, 2019 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce it has received its Containment Level II Pathogen and Toxin License from the…
Vivariant Laboratories Submits Cannabis Act Analytical Testing License Application
Toronto, September 16, 2018 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce the submission of it’s Analytical Testing license application in Health Canada’s new Cannabis…
Vivariant Laboratories Inc. Submits Licensed Dealer (LD) Application to Health Canada
Toronto, May 29, 2018 – Vivariant Laboratories Inc. – (the “Company” or “Vivariant”) is pleased to announce the submission of an application for a Licensed Dealer (LD) Permit to Health…
You must be logged in to post a comment.